Studies gut bacteria and their chemicals in fatty liver disease
Observes gut Ruminococcus gnavus and its chemicals in adults with fatty liver.
Plain-language title generated from the registry record
Registry title: An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines With Metabolic Dysfunction-associated Fatty Liver Disease
Key facts
- Where
- Guangzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adults with no liver disease and adults with metabolic dysfunction-associated fatty liver disease (MAFLD). It is an observational study with no treatment.
- Age
- Older than 18 years
- Sex
- Women and men
- Disease stage
- Either healthy people with no liver disease, or people diagnosed with MAFLD: fatty liver on imaging and/or at least 5% fat-filled liver cells on biopsy, plus at least one sign of metabolic syndrome.
- Earlier treatment
- Cannot have used laxatives, antibiotics, probiotics, prebiotics, proton pump inhibitors or other medicines that may affect gut bacteria in the past month.
Main reasons for not taking part
- Other causes of fatty liver, such as heavy alcohol use, malnutrition or Wilson's disease
- Severe disease of the liver, gut, kidneys or other organs
- Cancer or autoimmune disease
- Acute infection or inflammatory disease in the past month
- Medicines that may affect gut bacteria in the past month
Read by machine on 9 November 2026.
Where in China
- Zhujiang Hospital of Southern Medical UniversityGuangzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zhujiang Hospital
- Trial code
- NCT07455149
- Record updated
- 6 March 2026
- Original description
Investigating the association between intestinal Ruminococcus gnavus and its derived biogenic amines with metabolic dysfunction-associated fatty liver diseaseRead full original descriptionShow less
An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines With Metabolic Dysfunction-associated Fatty Liver Disease
Investigating the association between intestinal Ruminococcus gnavus and its derived biogenic amines with metabolic dysfunction-associated fatty liver disease
Inclusion: 1.Healthy individuals without a history of liver disease or related underlying diseases; or patients diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) according to the latest guideline, Guidelines for the Prevention and Treatment of Metabolic (Dysfunction-Associated/Non-Alcoholic) Fatty Liver Disease (2024 Edition), meeting the following criteria: (i) imaging-based diagnosis of fatty liver and/or liver biopsy showing ≥5% macrovesicular steatosis in hepatocytes; (ii) presence of at least one component of metabolic syndrome (MetS); and (iii) exclusion of other causes of fatty liver, including excessive alcohol consumption (weekly ethanol intake ≥210 g for men and ≥140 g for women), malnutrition, hepatolenticular degeneration (Wilson's disease), and other potential etiologies; 2.Willingness to participate in this study and to sign the informed consent form; 3.Age >18 years.
Exclusion: 1. History of severe organic diseases in the liver, gastrointestinal tract, kidneys, or other systems, malignant tumors, or autoimmune diseases; Patients who have had an acute infection or inflammatory disease within the past month; Use of laxatives, antibiotics, probiotics, prebiotics, proton pump inhibitors, or other medications that may affect the gut microbiota within the past month.